# US 10,246,513 B2 · Antibodies, compounds and derivatives thereof for use in the treatment of male infertility > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,246,513 B2 - Document ID: US10246513B2 - Status: Granted - Kind: B2 - Application number: 14/909,701 - Filed: 2014-08-04 - Published: 2016-06-16 - Granted: 2019-04-02 - Earliest claimed: 2013-08-07 - Assignees: Rigshospitalet Copenhagen University Hospital - Applicants: Rigshospitalet Copenhagen University Hospital - Inventors: Martin Blomberg Jensen - Web page: https://patentgrep.com/patent/US10246513B2 ## CPC - C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)} - A61K 38/1793: {for cytokines; for lymphokines; for interferons} - A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis - A61K 2039/505: {comprising antibodies} - C07K 2317/21: from primates, e.g. man - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a RANKL/OPGbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia. ## Claims ### Claim 1 A method of increasing sperm production in a male subject, comprising: selecting a male subject with spermatogenic failure; and administering to said male subject a therapeutically effective amount of a composition comprising Denosumab or an antigen binding domain thereof, or osteoprotegerin (OPG). ### Claim 2 (depends on 1) The method according to claim 1, wherein the composition comprises Denosumab. ### Claim 3 (depends on 1) The method according to claim 1, wherein the composition comprises a Denosumab antigen binding domain. ### Claim 4 (depends on 1) The method according to claim 1, wherein said method includes treating oligospermia. ### Claim 5 (depends on 1) The method according to claim 1, wherein said method includes treating azoospermia. ### Claim 6 (depends on 1) The method according to claim 1, wherein said composition is administered intravenously or subcutaneously. ### Claim 7 (depends on 1) The method according to claim 1, wherein said composition is administered subcutaneously. ### Claim 8 (depends on 1) The method according to claim 1, wherein said composition, is administered intra-intesticularly or in the genital region. ### Claim 9 (depends on 1) The method according to claim 1, wherein said composition, is administered in the scrotal region. ### Claim 10 (depends on 1) The method according to claim 1, wherein the composition is administered to a male subject who does not suffer from testicular cancer at any stage, which is detectable by histological analysis of a tissue sample of the testis from said subject. ### Claim 11 (depends on 1) The method according to claim 1, wherein said method includes treating oligospermia or azoospermia in male mammals, or increasing sperm production in male mammals. ### Claim 12 (depends on 1) The method according to claim 1, wherein said composition is in a pharmaceutical composition. ### Claim 13 A method of treating oligospermia or azoospermia in a male mammal, or of increasing sperm production in the male mammal, said method comprising administering a therapeutically effective amount of OPG (osteoprotegerin) or a fusion protein comprising OPG to the male mammal, wherein the male mammal has spermatogenic failure. ### Claim 14 A method of treating oligospermia or azoospermia in a male mammal, or of increasing sperm production in the male mammal, said method comprising administering a therapeutically effective amount of Denosumab to the male mammal, wherein the male mammal has spermatogenic failure.